Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current thinking in lipid lowering

C M Ballantyne1

  • 1Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.

The American Journal of Medicine
|July 31, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk.

bioRxiv : the preprint server for biology·2023
Same author

Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance.

International journal of obesity (2005)·2015
Same author

Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study.

International journal of obesity (2005)·2008
Same author

Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy.

Current medical research and opinion·2007
Same author

Glutamic acid decarboxylase antibodies are indicators of the course, but not of the onset, of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities Study.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2007
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Elevated low-density lipoprotein (LDL) cholesterol is a key factor in coronary artery disease (CAD). Assessing multiple risk factors and considering combination therapy can improve patient outcomes and treatment cost-effectiveness.

Area of Science:

  • Cardiology
  • Lipidology
  • Preventive Medicine

Background:

  • Elevated low-density lipoprotein (LDL) cholesterol is a primary driver of atherogenesis and coronary artery disease (CAD).
  • Other lipoprotein abnormalities, including reduced high-density lipoprotein (HDL) cholesterol and increased triglycerides, also correlate with CAD risk.
  • Non-lipid factors like homocysteine and C-reactive protein may contribute to cardiovascular risk stratification.

Purpose of the Study:

  • To review the role of various lipoprotein abnormalities and non-lipid factors in CAD.
  • To discuss the current US treatment guidelines for CAD risk assessment and management.
  • To explore the potential benefits of combination lipid-lowering therapy.

Main Methods:

  • Review of existing literature on lipoprotein metabolism and CAD.

Related Experiment Videos

  • Analysis of current US treatment guidelines focusing on LDL cholesterol.
  • Discussion of noninvasive imaging techniques for early CAD detection.

    • Main Results:

    • Current guidelines prioritize LDL cholesterol but acknowledge other risk factors.
    • Noninvasive imaging aids in early CAD detection and risk assessment.
    • The clinical impact of altering lipoprotein(a), LDL particle size, and homocysteine remains uncertain.

    Conclusions:

    • Global risk assessment is crucial for guiding treatment intensity.
    • Combination therapy targeting multiple lipid components may offer advantages over monotherapy.
    • Systematic screening to identify high-risk patients is essential for cost-effective treatment strategies.